Merck/Schering withdraw Loratadine/Montelukast NDA and Terminate Collaboration « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Merck/Schering withdraw Loratadine/Montelukast NDA and Terminate Collaboration

Posted on June 27, 2008 by crimsoncanary

Schering-Plough and Merck have withdrawn the NDA for the loratadine/montelukast and announced that they will terminate the joint venture which was formed to develop and market a fixed-combination product that would combine loratadine and montelukast. This follows the receipt of a not-approvable letter from the FDA in April 2008.

Filed under: Uncategorized | Tagged: D4, FDA, H1, Histamine, Histamine H1, Leucotriene, Leucotriene D4, Licensing, Loratadine, Merck, Montelukast, regulatory, Schering-Plough

« FDA recommends approval of Tolvaptan for Hyponatremia ProStrakan receives positive EMEA opinion for Rapinyl (Abstral) in cancer pain »

Leave a Reply